Antibody Therapy Market Size to Attain USD 737.59 Bn by 2033

Prathamesh

3 months ago

The global antibody therapy market size was valued at USD 240.90 billion in 2023 and is projected to rake around USD 737.59 billion by 2033 growing at a CAGR of 11.84% from 2024 to 2033.

Antibody Therapy Market Size 2024 to 2033

Key Points

North America dominated the market with a major market share of 34% in 2023.
By type, the monoclonal antibody segment held the largest market share in 2023.
By end user, the hospital segment has captured the largest market share of 48% in 2023.

The antibody therapy market is experiencing significant growth due to its promising potential in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibody therapy, also known as immunotherapy, involves the use of monoclonal antibodies (mAbs) or polyclonal antibodies to target specific antigens, thereby modulating the immune response to combat diseases. This approach has gained traction in recent years as a result of advancements in biotechnology, leading to the development of novel antibody-based therapeutics with improved efficacy and safety profiles.

Get a Sample: https://www.precedenceresearch.com/sample/3891

List of Contents

Toggle

Growth Factors

Several factors contribute to the growth of the antibody therapy market. Firstly, the increasing prevalence of chronic diseases such as cancer and autoimmune disorders has spurred the demand for innovative treatment options with fewer side effects. Antibody therapy offers targeted treatment, minimizing damage to healthy tissues and improving patient outcomes. Secondly, ongoing research and development activities in biotechnology and immunology have led to the discovery of new antibody targets and the development of more potent antibodies with enhanced therapeutic properties. Additionally, the approval of several monoclonal antibody drugs by regulatory authorities has bolstered confidence in antibody-based therapies among healthcare providers and patients, driving market growth further.

Furthermore, the expanding applications of antibody therapy beyond oncology, including in the treatment of inflammatory and infectious diseases, present lucrative opportunities for market players. The advent of technologies such as antibody-drug conjugates (ADCs) and bispecific antibodies has further expanded the therapeutic potential of antibody-based drugs, fueling market expansion. Moreover, the growing trend of personalized medicine and targeted therapies has propelled the demand for customized antibody-based treatments tailored to individual patients’ genetic makeup and disease profiles.

Region Analysis:

The antibody therapy market exhibits a global presence, with key regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market, attributed to the presence of leading pharmaceutical and biotechnology companies, robust research infrastructure, and favorable regulatory policies promoting innovation and drug development. The United States, in particular, accounts for a significant share of the global antibody therapy market, driven by high healthcare expenditure, increasing prevalence of chronic diseases, and strong market competition.

Europe follows closely behind, characterized by a growing geriatric population and rising healthcare expenditure in countries such as Germany, the United Kingdom, and France. The Asia Pacific region is poised for substantial growth, fueled by improving healthcare infrastructure, rising disposable incomes, and a growing focus on healthcare modernization in countries like China, Japan, and India. Moreover, increasing investments in biotechnology and clinical research, along with a large patient pool, contribute to the region’s attractiveness for antibody therapy market players.

Antibody Therapy Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2033	CAGR of 11.84%
Global Market Size in 2023	USD 240.90 Billion
Global Market Size by 2033	USD 737.59 Billion
U.S. Market Size in 2023	USD 57.33 Billion
U.S. Market Size by 2033	USD 175.55 Billion
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Type and By End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

SWOT Analysis:

Strengths:

Antibody therapy offers targeted treatment with minimal side effects, improving patient outcomes.
Continuous advancements in biotechnology and immunology lead to the development of more potent antibodies.
Approval of monoclonal antibody drugs by regulatory authorities enhances market credibility.

Weaknesses:

High costs associated with antibody therapy may limit access for certain patient populations.
Development of resistance to antibody-based drugs poses challenges in long-term efficacy.

Opportunities:

Expanding applications of antibody therapy in treating various diseases beyond oncology.
Advancements in technology, such as ADCs and bispecific antibodies, broaden therapeutic possibilities.
Growing demand for personalized medicine drives the need for customized antibody-based treatments.

Threats:

Competition from alternative therapies, including small molecule drugs and gene therapies.
Stringent regulatory requirements and lengthy approval processes may hinder market growth.
Potential risks of adverse reactions and immune-related adverse events require careful monitoring and management.

Recent Developments

In July 2022, AstraZeneca acquired TeneoTwo, strengthening its hematological cancer pipeline with a clinical-stage T-cell engager.
In December 2023, Bristol Myers Squibb augmented its radiopharmaceutical platform with the acquisition of RayzeBio.
In June 2022, Galapagos acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies.
In June 2023, Lilly acquired cancer antibody drug startup Emergence.
In September 2021, Boehringer Ingelheim acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches further.
In June 2023, Lonza announced the acquisition of Synaffix, strengthening its antibody-drug conjugates offering.